Drug Trial Radar · NCT00664846
Standard Medical Management in Secondary Prevention of Ischemic Stroke in China
Last checked: Nov 19, 2026Latest source record: Apr 11, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,000
Planned (sponsor's estimate)
Start
Apr 2008
Primary completion
Dec 2010
Study completion Apr 2011
Sponsor
- Lead sponsor
- Peking Union Medical College HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 23, 2008
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purposes of the study are to analyse the cross-section data of secondary stroke prevention in China and to carry out a standard medical management including medicine and interactive education program,and to evaluate the efficacy and safety of the standard medical management in secondary stroke prevention.
Conditions
- Stroke
Interventions
Aspirin / Clopidogrel, Atorvastatin / SimvastatinDrug
Standard Medical Management,including antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide) .
Asprin / Clopidogrel, Atorvastatin / SimvastatinDrug
Antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary
Primary outcomes
What the sponsor says the trial is designed to measure.
- Success Rate of standard medical managementTime frame: 1 year after enrolled
Locations
46 sites in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hosptial
Beijing, Beijing Municipality, China
China Pla General Hospital
Beijing, Beijing Municipality, China
Beijing Daxing District Hospital
Beijing, Beijing Municipality, China
Beijing Ji Shui Tan Hospital,the 4Th Medical College of Peking University
Beijing, Beijing Municipality, China
Beijing Shijitan Hospital
Beijing, Beijing Municipality, China
Beijing Tiantan Hospital
Beijing, Beijing Municipality, China
China Rehabilition Research Center
Beijing, Beijing Municipality, China
General Hospital of Navy
Beijing, Beijing Municipality, China
Luhe Hospital of Tongzhou Distict Beijing
Beijing, Beijing Municipality, China
No 263 Hospital of Pla
Beijing, Beijing Municipality, China
No 309 Hospital of Pla
Beijing, Beijing Municipality, China
Peking University Third Hospital
Beijing, Beijing Municipality, China
Pinggu County Hospital Beijing
Beijing, Beijing Municipality, China
Xuanwu Hospital Capital Medical University
Beijing, Beijing Municipality, China
Daping Hospital
Chongqing, Chongqing Municipality, China
Southwest Hospital
Chongqing, Chongqing Municipality, China
Guangzhou First Municipal People'S Hospital
Guangzhou, Guangdong, China
The First Affiliated Hospital,Sun Yat-Sen Unversity
Guangzhou, Guangdong, China
The First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
The Third Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Yutian County Hospital
Yutian, Hebei, China
Hebei North University
Zhangjiakou, Hebei, China
The First Hospital of Harbin Medical University
Harbin, Helongjiang, China
The Second Hospital of Harbin Medical University
Harbin, Helongjiang, China
Henan Provincial People'S Hospital
Zhengzhou, Henan, China
The Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China
Xiangya Hospital of Centre-South University
Changsha, Hunan, China
Inner Mongolia Baotou City Central Hospital
Baotou, Inner Mongolia, China
The Appurtenant Hospital of Chifeng University
Chifeng, Inner Mongolia, China
Jiangsu Province Hospital
Nanjing, Jiangsu, China
Nanjing General Hospital of Nanjing Military Command
Nanjing, Jiangsu, China
The Affiliated Drumtower Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China
Jilin University
Changchun, Jilin, China
The Third People'S Hospital of Dalian
Dalian, Liaoning, China
The First Affiliated Hospital of China Medical Sciences University
Shenyang, Liaoning, China
Qinghai Provincial People'S Hospital
Xining, Qinghai, China
Qilu Hospital of Shangdong University
Jinan, Shandong, China
The Second Hospitalof Shangdong University
Jinan, Shandong, China
Huashan Hospital Fudan University
Shanghai, Shanghai Municipality, China
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.